Citations

Clear

9383 citation(s) found for "Thomas, PS".

Stearoyl-CoA Desaturase 1 Is a Novel Molecular Therapeutic Target for Clear Cell Renal Cell Carcinoma
Roemeling, Christina A. Von , Marlow, Laura A. , Wei, Johnny J. , Caulfield, Thomas R. , Wu, Kevin J. , Tan, Winston , Copland, John A. , Cooper, Simon JR , Tun, Han W. , Caulfield, Thomas R , von Roemeling, Christina A , Marlow, Laura

Mayo Clinic

Clinical Cancer Research | May 1, 2013 | Volume: 19 | Issue: 9 | Pages: 2368-2380

10.1158/1078-0432.ccr-12-3249 | PMID 23633458 Get It

Abstract Purpose: We set out to identify Stearoyl-CoA desaturase 1 (SCD1) as a novel molecular target in clear cell renal cell carcinoma (ccRCC) and examine its role in tumor cell growth and viability in vitro and in vivo independently as well as in combination with current U.S. Food and Drug Administration (FDA)-approved regimens. Experimental Design: Patient normal and ccRCC tissue samples and cell lines were examined for SCD1 expression. Genetic knockdown models and targeted inhibition of SCD1 through use of a small molecule inhibitor, A939572, were analyzed for growth, apoptosis, and alterations in gene expression using gene array analysis. Therapeutic models of synergy were evaluated utilizing pharmacologic inhibition of SCD1 with the tyrosine kinase inhibitors (TKI) sunitinib and pazopanib, and the mTOR inhibitor temsirolimus. Results: Our studies identify increased SCD1 expression in all stages of ccRCC. Both genetic knockdown and pharmacologic inhibition of SCD1 decreased tumor cell proliferation and induced apoptosis in vitro and in vivo. Upon gene array, quantitative real-time PCR, and protein analysis of A939572-treated or SCD1 lentiviral knockdown samples, induction of endoplasmic reticulum stress response signaling was observed, providing mechanistic insight for SCD1 activity in ccRCC. Furthermore, combinatorial application of A939572 with temsirolimus synergistically inhibited tumor growth in vitro and in vivo. Conclusions: Increased SCD1 expression supports ccRCC viability and therefore we propose it as a novel molecular target for therapy either independently or in combination with an mTOR inhibitor for patients whose disease cannot be remedied with surgical intervention, such as in cases of advanced or metastatic disease. Clin Cancer Res; 19(9); 2368–80. ©2013 AACR.
Hypertension in Pregnancy Is a Risk Factor for Microalbuminuria Later in Life
Kattah, Andrea G. , Asad, Reem , Scantlebury, Dawn C. , Bailey, Kent R. , Wiste, Heather J. , Hunt, Steven C. , Kardia, Sharon L. R., Garovic, Vesna D. , Mosley, Thomas H. , Turner, Stephen T. , Garovic, Vesna D

Mayo Clinic

The Journal of Clinical Hypertension | April 29, 2013 | Volume: 15 | Issue: 9 | Pages: 617-623

10.1111/jch.12116 | PMID 24034653 Get It

The authors aimed to compare renal function by estimated glomerular filtration rate and albuminuria in 3 groups of women: nulliparous women, women with a history of normotensive pregnancies, and women with a history of at least one hypertensive pregnancy. Women who participated in the second F amily B lood P ressure P rogram S tudy visit (2000–2004) and had serum creatinine and urine albumin measurements (n=3015) were categorized as having had no pregnancy lasting >6 months (n=341), having had only normotensive pregnancies (n=2199), or having had at least 1 pregnancy with hypertension (n=475) based on a standardized questionnaire. Women who reported having had at least one pregnancy with hypertension were significantly more likely to be hypertensive (75.6% vs 59.4%, P <.001), diabetic (34.2% vs 27.3%, P ≤.001), and have higher body mass index (32.8 vs 30.5, P <.001) than those who reported normotensive pregnancies. There was a significantly greater risk of microalbuminuria (urine albumin‐creatinine ratio >25 mg/g) in those who reported at least one pregnancy with hypertension ( odds ratio, 1.37; confidence interval, 1.02–1.85; P =.04) than in those with normotensive pregnancies, after adjusting for risk factors for chronic kidney and cardiovascular disease. Hypertension in pregnancy is associated with an increased risk of future microalbuminuria.
Adult‐onset systemic Langerhans cell histiocytosis mimicking inflammatory bowel disease: the value of skin biopsy and review of cases of Langerhans cell histiocytosis with cutaneous involvement seen at the Mayo C
Podjasek, Joshua O., Loftus, Conor G., Smyrk, Thomas C. , Wieland, Carilyn N.

Mayo Clinic

International Journal of Dermatology | April 29, 2013 | Volume: 53 | Issue: 3 | Pages: 305-311

10.1111/j.1365-4632.2012.05716.x | PMID 23621577 Get It

AbstractBackgroundLangerhans cell histiocytosis (LCH) is frequently known to involve multiple organ systems. However, gastrointestinal involvement by LCH is rare.MethodsWe describe a 68‐year‐old woman with a 3‐year history of intermittent diarrhea initially diagnosed as inflammatory bowel disease. She was subsequently found to have systemic LCH with involvement of the gastrointestinal tract, lungs, liver, and skin after skin biopsy was performed. A retrospective review of patients with cutaneous involvement of LCH seen at the Mayo Clinic over the past 15 years was conducted. The presence of systemic disease as well as specific organ system involvement was reviewed.ResultsTwenty‐four patients with cutaneous LCH were identified. Besides our case, one other patient with both gastrointestinal and cutaneous involvement was identified. This patient died at six months of age. No other adult‐onset cases were identified.ConclusionsGastrointestinal involvement with LCH is rare, can be easily misdiagnosed, and likely portends a poor prognosis. In patients with ill‐defined systemic symptoms, cutaneous exam and biopsy have the potential to diagnose systemic disease.
A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and 90yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B‐cell non‐Hodgkin lymphoma
Wiseman, Gregory A., Maurer, Matthew J. , Micallef, Ivana N. , Nowakowski, Grzegorz S. , Ansell, Stephen M. , Inwards, David J. , Porrata, Luis F. , Link, Brian K. , Johnston, Patrick B. , Allmer, Cristine, Asmann, Yan W. , Ballas, Zuhair K. , Smith, Brian J., Weiner, George J. , Witzig, Thomas E. , Habermann, Thomas M. , Colgan, Joseph P. , Zent, Clive S. , Shanafelt, Tait D. , Gupta, Mamta , Smith, Brian J., Maurer, Matthew , Link, Brian K , Weiner, George

Mayo Clinic

American Journal of Hematology | April 26, 2013 | Volume: 88 | Issue: 7 | Pages: 589-593

10.1002/ajh.23460 | PMID 23619698 Get It

Radioimmunotherapy (RIT) for relapsed indolent non‐Hodgkin lymphoma produces overall response rates (ORR) of 80% with mostly partial remissions. Synthetic CpG oligonucleotides change the phenotype of malignant B‐cells, are immunostimulatory, and can produce responses when injected intratumorally and combined with conventional radiation. In this phase I trial, we tested systemic administration of both CpG and RIT. Eligible patients had biopsy‐proven previously treated CD20+ B‐cell NHL and met criteria for RIT. Patients received rituximab 250 mg/m2 days 1,8, and 15; 111In‐ibritumomab tiuxetan days 1, 8; CpG 7909 days 6, 13, 20, 27; and 0.4 mCi/kg of 90Y‐ibritumomab tiuxetan day 15. The doses of CpG 7909 tested were 0.08, 0.16, 0.32 (six patients each) and 0.48 mg/kg (12 patients) IV over 2 hr without dose limiting toxicity. The ORR was 93% (28/30) with 63% (19/30) complete remission (CR); median progression free survival of 42.7 months (95% CI 18‐NR); and median duration of response (DR) of 35 months (4.6–76+). Correlative studies demonstrated a decrease in IL10 and TNFα, and an increase in IL1β, in response to therapy. CpG 7909 at a dose of 0.48 mg/kg is safe with standard RIT and produces a high CR rate and long DR; these results warrant confirmation. Am. J. Hematol. 88:589–593, 2013. © 2013 Wiley Periodicals, Inc.
Tips and Tricks for MR Angiography of Pediatric and Adult Congenital Cardiovascular Diseases
Young, Phillip M. , McGee, Kiaran P. , Pieper, Matthew S., Binkovitz, Larry A. , Matsumoto, Jane M., Kolbe, Amy B. , Foley, Thomas A. , Julsrud, Paul R.

Mayo Clinic

American Journal of Roentgenology | April 25, 2013 | Volume: 200 | Issue: 5 | Pages: 980-988

10.2214/ajr.12.9632 | PMID 23617479 Get It

UIP Diagnosed at Surgical Lung Biopsy, 2000–2009: HRCT Patterns and Proposed Classification System
Gruden, James F. , Panse, Prasad M., Leslie, Kevin O., Tazelaar, Henry D. , Colby, Thomas V. , Tazelaar, Henry D.

Mayo Clinic

American Journal of Roentgenology | April 25, 2013 | Volume: 200 | Issue: 5 | Pages: W458-W467

10.2214/ajr.12.9437 | PMID 23617514 Get It

Transoral laser microsurgery for the unknown primary: Role for lingual tonsillectomy
Nagel, Thomas H. , Hinni, Michael L., Hayden, Richard E. , Lott, David G.

Mayo Clinic

Head & Neck | April 25, 2013 | Volume: 36 | Issue: 7 | Pages: 942-946

10.1002/hed.23372 | PMID 23616406 Get It

BackgroundWe conducted a retrospective review of patients with unknown primary head and neck cancer who underwent a transoral laser microsurgery (TLM)‐assisted search for an occult tumor.MethodsFifty‐two patients at a single center with unknown primaries of squamous cell carcinoma (SCC) were treated with a surgical algorithm.ResultsThe overall rate of primary tumor identification was 75% (39 of 52 patients). When selecting those cases in which a TLM algorithm with lingual tonsillectomy was utilized, the detection rate was 86% (31 of 36). Tumors were most commonly found in the lingual (65.0%) and palatine tonsils (27.5%). When directed biopsies did not locate a tumor, a higher yield was obtained with the addition of a lingual tonsillectomy in 8 patients.ConclusionA surgical algorithm for the unknown primary that includes TLM‐assisted techniques, including a lingual tonsillectomy, offers the greatest likelihood of successfully detecting the location of occult primary tumors. © 2014 Wiley Periodicals, Inc. Head Neck 36: 942–946, 2014
Mediation of smoking-associated postoperative mortality by perioperative complications in veterans undergoing elective surgery: data from Veterans Affairs Surgical Quality Improvement Program (VASQIP)—a cohort study
Singh, Jasvinder A. , Hawn, Mary T. , Campagna, Elizabeth J., Henderson, William G., Richman, Joshua , Houston, Thomas K. , Singh, Jasvinder A

Mayo Clinic

BMJ Open | April 19, 2013 | Volume: 3 | Issue: 4 | Pages: e002157

10.1136/bmjopen-2012-002157 | PMID 23604347 Get It

Objective To assess the mediation of smoking-associated postoperative mortality by postoperative complications. Design Observational cohort study. Setting Using data from the Veterans Affairs (VA) Surgical Quality Improvement Programme, a quality assurance programme for major surgical procedures in the VA healthcare system, we assessed the association of current smoking at the time of the surgery with 6-month and 1-year mortality. Primary and secondary outcome measures Using mediation analyses, we calculated the relative contribution of each smoking-associated complication to smoking-associated postoperative mortality, both unadjusted and adjusted for age, race/ethnicity, work relative value unit of the operation, surgeon specialty, American Society of Anesthesiologists class and year of surgery. Smoking-associated complications included surgical site infection (SSI), cardiovascular complications (myocardial infarction, cardiac arrest and/or stroke) and pulmonary complications (pneumonia, failure to wean and/or reintubation). Results There were 186 632 never smokers and 135 741 current smokers. The association of smoking and mortality was mediated by smoking-related complications with varying effects. In unadjusted analyses, the proportions of mediation of smoking to 6-month mortality explained by the complications were as follows: SSIs 22%, cardiovascular complications 12% and pulmonary complications 89%. In adjusted analyses, the per cents mediated by each complication were as follows: SSIs 2%, cardiovascular complications 4% and pulmonary complications 22%. In adjusted analyses for 1-year mortality, respective per cents mediated were 2%, 3% and 16%. Conclusions Pulmonary complications, followed by cardiovascular complications and SSIs were mediators of smoking-associated 6-month and 1-year mortality. Interventions targeting smoking cessation and prevention and early treatment of pulmonary complications has the likelihood of reducing postoperative mortality after elective surgery.
FCGR2A and FCGR3A polymorphisms in classical Hodgkin lymphoma by Epstein–Barr virus status
Ghesquières, Hervé , Link, Brian K. , Maurer, Matthew J. , Cunningham, Julie M. , Novak, Anne J. , Larrabee, Beth R. , Allmer, Cristine, Ansell, Stephen M. , Cerhan, James R. , Doǧan, Ahmet , Slager, Susan L. , Habermann, Thomas M. , Maurer, Matthew , Cerhan, James R , Link, Brian K

Mayo Clinic

Leukemia & Lymphoma | April 19, 2013 | Volume: 54 | Issue: 11 | Pages: 2571-2573

10.3109/10428194.2013.796048 | PMID 23597143 Get It

Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project
Harrison, Claire , Kiladjian, Jean‐Jacques , Lengfelder, Eva , Passamonti, Francesco , Besses, Carlos , Gisslinger, Heinz , Samuelsson, Jan , Verstovšek, Srđan , Pardanani, Animesh , Cervantes, Francisco , Tefferi, Ayalew , Barbui, Tiziano , Barosi, Giovanni , Mesa, Ruben A. , Finazzi, Guido , McMullin, Mary Frances , Vannucchi, Alessandro M. , Hoffman, Ronald , Verstovsek, Srdan , Kiladjian, Jean-Jacques , Passamonti, Francesco

Mayo Clinic

Blood | April 16, 2013 | Volume: 121 | Issue: 23 | Pages: 4778-4781

10.1182/blood-2013-01-478891 | PMID 23591792 Get It

Key Points Evidence exists that ELN criteria for response in ET and PV issued in 2009 do not provide relevant measures of benefit for patients. Revised recommendations for assessing response are provided.